Elizabeth A. Thomas
Department of Molecular Biology
The Scripps Research Institute
MB-10
10550 N. Torrey Pines Rd.
USA
Name/email consistency: high
- Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Thomas, E.A. Mol. Neurobiol. (2009)
- The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Thomas, E.A., Coppola, G., Desplats, P.A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K.M., Borok, J.F., Herman, D., Geschwind, D.H., Gottesfeld, J.M. Proc. Natl. Acad. Sci. U.S.A. (2008)
- Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. Thomas, E.A., Yao, J.K. Schizophr. Res. (2007)
- Striatal specificity of gene expression dysregulation in Huntington's disease. Thomas, E.A. J. Neurosci. Res. (2006)
- Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Thomas, E.A. Mol. Neurobiol. (2006)
- From pharmacotherapy to pathophysiology: emerging mechanisms of apolipoprotein D in psychiatric disorders. Thomas, E.A., Copolov, D.L., Sutcliffe, J.G. Curr. Mol. Med. (2003)
- Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. Thomas, E.A., George, R.C., Sutcliffe, J.G. Prostaglandins Leukot. Essent. Fatty Acids (2003)
- Oleamide-induced modulation of 5-hydroxytryptamine receptor-mediated signaling. Thomas, E.A., Carson, M.J., Sutcliffe, J.G. Ann. N. Y. Acad. Sci. (1998)
